Zobrazeno 1 - 10
of 435
pro vyhledávání: '"Victor L. Serebruany"'
Publikováno v:
TH Open, Vol 01, Iss 02, Pp e101-e105 (2017)
Abstract Background The U.S. Food and Drug Administration (FDA) Adverse Event (AE) Reporting System (FAERS) is a global passive surveillance repository requiring mandatory updates by pharmaceutical manufacturers. Oral antiplatelet agents (OAAs) inc
Externí odkaz:
https://doaj.org/article/ca4f33bbf1d245a181b51523dcd89fbe
Autor:
Yanti Nasyuhana Sani, Lim Sheau Chin, Lim Luen Hui, Nur Elyana Yazmin Mohd Redhuan Shah Edwin, Goh Teck Hwa, Victor L. Serebruany, Yuen Kah Hay
Publikováno v:
Cardiology Research and Practice, Vol 2013 (2013)
Background. The CYP2C19*2 allele may be associated with a reduced antiplatelet effect for clopidogrel. Here, we assessed whether CYP2C19*2 alleles correlate with clopidogrel responsiveness following the administration of clopidogrel in healthy Malays
Externí odkaz:
https://doaj.org/article/e7822358522b45819040d1f196eda22d
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year
Autor:
Victor L. Serebruany, Jean-Francois Tanguay, Milana L. Gurvich, Thomas A. Marciniak, Dan Atar
Publikováno v:
The American Journal of Medicine. 136:484-488
Autor:
Victor L. Serebruany, Jean-Francois Tanguay, Milana L. Gurvich, Thomas A. Marciniak, Dan Atar
Publikováno v:
American Journal of Therapeutics.
Publikováno v:
TH Open, Vol 05, Iss 04, Pp e503-e506 (2021)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Background Cardiovascular benefits of aggressive dual antiplatelet therapy may be associated with extra risks including bleeding, cancer, and infections discovered first for prasugrel in the TRial to assess Improvement in Therapeutic Outcomes by opti
Autor:
Victor L. Serebruany, Jean-François Tanguay, Wiktor Kuliczkowski, Eric Heidel, Moo Hyun Kim, Dan Atar
Publikováno v:
The American journal of medicine. 135(11)
Bleeding remains a complication during dual antiplatelet therapy (DAPT) for acute coronary syndrome (ACS). Some data suggest a link between bleeding and worsened vascular outcomes. However, this association is unclear, due to omitting of minor bleedi
Publikováno v:
Reviews in Cardiovascular Medicine, Vol 22, Iss 3, Pp 553-555 (2021)
No abstract present.
Autor:
Julia Docenko, Nikita Lomakin, Victor L. Serebruany, Arthur Melkumyants, Liudmila Buryachkovskaya
Publikováno v:
Reviews in Cardiovascular Medicine, Vol 22, Iss 3, Pp 549-551 (2021)
No abstract present.
Autor:
Enze Jin, Victor L. Serebruany, Jia-Xin Li, Moo Hyun Kim, Jin-Yeong Han, Soo Jin Kim, Kwang Min Lee, Kai Song, LongZhe Guo
Publikováno v:
Clinical & Experimental Thrombosis and Hemostasis. 6:6-11
Autor:
James Swan, Cheol-Whan Lee, Kiyuk Jang, Wolfgang Eisert, Mario Alberto Benavides, Victor L. Serebruany, Junghan Yoon, Jean-François Tanguay, Moo Hyun Kim, Thomas A. Marciniak, Hector A. Cabrera-Fuentes
Publikováno v:
American Journal of Therapeutics
Background Excess vascular deaths in the PLATO trial comparing ticagrelor to clopidogrel have been repeatedly challenged by the Food and Drug Administration (FDA) reviewers and academia. Based on the Freedom of Information Act, BuzzFeed won a court o